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Summary 
Interleukin (IL) 4 is a multifunctional T cell-derived cytokine that inhibits cytokine production 
and certain effector functions in human monocytes, while enhancing others. We show that II:4 
may contribute to the downregulation and resolution of an inflammatory response by selectively 
promoting expression of the IL-1 receptor antagonist (IL-lra) that blocks the action of IL-1. IL-lra 
specifically binds to the II.-1 receptor without initiating signal transduction. Peripheral blood 
monocytes obtained from cancer  patients,  before and  immediately after  a  regimen of II-4 
immunotherapy, were examined for IL-lra gene expression.  After II.-4 therapy, monocytes from 
the patients showed a marked increase in Iblra mRNA. This selective induction of Iblra mRNA 
in circulating monocytes was reflected by significantly enhanced serum levels of Iblra (p <0.01) 
during II-4 therapy, which declined after II.-4 treatment. In vitro analysis of II-4 regulation of 
monocytes from normal individuals revealed a dose-dependent induction of II.-lra mRNA within 
2-4 h after stimulation without a concomitant effect on the expression of Ibl mRNA. Increased 
IL-lra mRNA was not due to RNA stabilization,  but occurred at the level of transcription. 
In the presence of LPS, IL-4 not only augmented Iblra levels, but markedly inhibited LPS-induced 
II.-1 mRNA expression.  The selective upregulation of IL-lra by resting or activated monocytes, 
coupled with inhibition of II-1 production by activated monocytes, as we demonstrate both in 
vitro and in vivo, suggests that II.-4 may prove clinically useful as a systemic antiinflammatory 
agent. 
T 
he balance between immune responses to infectious agents 
and antigens and the development of immune-mediated 
host injury depends, to a large extent, on the elicitation and 
actions of soluble immunoregulatory cytokines. Cytokines 
such as Ib2 and IFN-% which promote the development of 
cell-mediated immunity, are derived from Thl helper T lym- 
phocytes, whereas Th2 cells promote primarily B cell devel- 
opment and function through the production of Ib4, -5, -6, 
and -10  (for review,  see reference  1). Although originally 
characterized in mice, Thl and Th2 subsets have recently been 
identified in humans through the isolation of CD4 + clones 
from  patients  with  different  pathologic  profiles  (2,  3). 
Emerging evidence suggests that in addition to regulating 
the humoral immune response (4, 5), cytokines secreted by 
Th2 ceUs may also function to suppress call-mediated im- 
mune pathways normally potentiated by Thl-derived cyto- 
kines. For example, II:4 has been shown to inhibit the produc- 
tion  of monokines  (6-8),  PGE2, and  metalloproteinases 
induced by IFN-~/and other stimuli (6, 7, 9-11), and by in- 
hibiting the expression of Fear (12, D), IL-4 may limit phago- 
cytosis and the release of reactive oxygen intermediates. 
These in vitro observations of an antiinflammatory role 
for IL-4 have recently been extended in studies in vivo. Pa- 
tients participating in a clinical trial using Ib4 as an anticancer 
agent displayed altered monocyte functions in which post- 
therapy monocytes exhibited a significantly diminished ability 
to secrete PGE2 and superoxide anion (7). After isolation of 
the monocytes from the patients receiving IL4 therapy, the 
cells recovered their ability to generate IL-1 when challenged 
in vitro with LPS (7).  However,  based on recent evidence 
that Ib4 induces the II:1 receptor antagonist (Iblra) 1 in a 
monocytic cell line (14), and augments ILlra production in 
LPS-stimulated blood monocytes (15, 16), we subsequently 
evaluated patient monocytes for II~lra  gene expression be- 
fore and after IL-4 therapy. IL-lra, a 22-25-kD glycosylated 
protein (17, 18), binds to the human type I and type II Ibl 
receptors with similar affinity as ID1B and IL-lc~, but does 
1 Abbreviations  used in this paper:  Cx, cycloheximide; ILlra, IL-1 receptor 
antagonist. 
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or transduce an activation signal  (19). After systemic  I1-4 
therapy, we found that monocytes from the patients expressed 
increased  mRNA for I1-1ra that was reflected by a 10-fold 
increase in serum I1.1ra levels. Characterization of the mech- 
anism by which I1-4 regulates I1-1ra mRNA production and 
peptide secretion revealed rapid and transient induction that 
was dependent on increased transcription. These data, together 
with the ability of I1.4 to suppress inducible I1.1 synthesis, 
implicate IL-4 as a unique systemic antiinflammatory agent. 
Materials and Methods 
Monocyte Isolation and Culture.  PBMC were obtained by leu- 
kapheresis (National Institutes of Health Department of Transfu- 
sion Medicine)  with subsequent centrifugation of the cells through 
Ficoll-Hypaque (7). Monocyte populations were then purified 
(90-95%  CD14  +) by counterflow centrifugal elutriation  (20). 
Monocytes were resuspended in  DMEM  (Cellgro/Mediatech, 
Washington, DC) supplemented with 50/~g/ml gentamicin sul- 
fate (Whittaker Bioproducts, Walkersville,  MD) and 2 mM L-glu- 
tamine (Gibco, Grand Island, NY) and cultured in suspension in 
17  x  100-ram  polypropylene  tubes (Falcon/Becton  Dickinson Lab- 
ware, Lincoln Park, NJ) or as adherent monohyers in 24-weU plates 
(Costar Corp., Cambridge, MA) (106/ml) in the absence or pres- 
ence of  recombinant  human Ib4 (Genzyme  Corp., Cambridge, MA 
and Immunex Corp., Seattle, WA) which by limulus assay con- 
tained <0.06 EU/ml (1 EU =  0.1 ng/ml endotoxin, the limit of 
detection of the assay; courtesy of  Dr. D. Hochstein, Federal  Drug 
Administration, Bethesda, MD). Cultures were then stimulated 
or not with LPS (LPS, Escherichia coli 055.B5, Difco Laboratories, 
Inc., Detroit,  MI) for the indicated time periods. 
Patient Populations.  Patients  with renal cell carcinoma or with 
malignant mdanoma were given rlL-4 (generously  provided  by Dr. 
S. Gillis, Immunex Corp., and Dr. E. Bradley,  Sterling Pharmaceu- 
tical, Malvern, PA; sp act 1.5  x  107 U/rag) at doses ranging from 
10 to 20 I~g/kg body weight three times daily for 3-5 d (7). One 
day before initiation, during, and at indicated intervals after 11.,4 
immunotherapy, patients were leukapheresed and the monocytes 
were purified by elutriation. Monocytes were processed immedi- 
ately or cryopreserved  after isolation enabling pre- and posttherapy 
cells to be thawed and analyzed simultaneously (7). AU patients 
were treated according to National Cancer Institute Institutional 
Review Board approved protocols and signed informed consent be- 
fore treatment. 
Northern Blot Analysis.  Monocytes  were cultured in suspension 
(10Vml in 17  x  100-mm tubes) with or without IL-4, washed 
with PBS, and total cellular RNA was isolated by using a one-step 
acid guanidinium-thiocyanate-phenol-chloroform  procedure (21). 
RNA  samples (5  #g)  were electrophoresed in  1%  formalde- 
hyde-agarose gels, blotted onto nitrocellulose filters (Schleicher  & 
Schuell, Inc., Keene, NH) and prehybridized at 42~  for at least 
4 h before hybridization at 42~  with 32p-labeled human Ibl~ 
(22), IL-lra (18), (generously provided by Dr. D. Carter, UpJohn 
Co.,  Kalamazoo, MI),  He7,  or glyceraldehyde  3-phosphate de- 
hydrogenase  (GAFDH) (23) eDNA probes. The blots were washed 
twice in 2x SSC, 0.1% SDS for 15 min at 22~  and once in 0.1x 
SSC, 0.1% SDS for 30 rain at 65~  After washing, the filters  were 
exposed to a phosphor screen (Molecular Dynamics, Sunnyvale, 
CA) for 1-24 h.  Scanned images were obtained using a Phos- 
pliorlmager and Image Quant software (Molecular Dynamics), 
transferred and reproduced using Macintosh Adobe Photoshop, 
Image and Aldus pagemaker (Apple Computer, Inc., Cupertino, 
CA) software  and printed on a color printer (Phaser CP; Tektronix, 
Inc., Beaverton, OR). 
Nuclear Run-offAssays.  Monocytes  (5  x  107) were cultured in 
the presence or absence of lb4 (1,000 U/ml) and nuclei were iso- 
lated by lysis of the cells in 10 mM Tris-HC1, pH 7.5, 2 mM 
MgC12, 3 mM CaCI2, 3 k~M DTT, 0.3 M sucrose and 0.5% Triton 
X-100 and disruption  with a Dounce homogenizer  (size  B; Wheaton 
Scientific, Millville,  NJ). The disrupted cells were then centrifuged 
at 3000 g for 10 min at 4~  through a cushion of 30% sucrose 
and 0.5% Triton X-100 to pellet the nuclei. For the runoff assay, 
100/~1 of reaction buffer (10 mM Tris-HC1, pH 8.0, 5 mM MgC12, 
0.3 M KC1 and 5/~M DTT) with 100 mM ATP, CTP, and GTP, 
and 100/~Ci ot-[32p] UTP (>760 Ci/mmole,  Amersham Corp., 
Arlington Heights, IL) was added to each sample of nuclei. After 
incubation with continuous shaking at 30~  for 30 min, nuclear 
transcripts were purified (21) and hybridized at 62~  for 36 h to 
nitrocellulose  filters  on which 5/zg oflinearized, denatured plasmid 
DNA had been immobilized. The filters were then washed twice 
for 30 rain in 2x  SSC, 0.1% SDS at 62~  treated with IkNase 
A (10/zg/ml) in 2x  SSC for 30 rain at 37~  and washed with 
2x  SSC, 0.1% SDS for 30 min at 37~  The filters were exposed 
to a phosphor screen for 3-16 h and phosphorimages  were scanned. 
IL.lra ELISA.  IL-lra  peptide was detected using an ELISA kit 
purchased from R&D Systems, Inc. (Minneapolis, MN). 
Results 
IL, lra  Is  Increased  in  Cancer Patients  Receiving  vii.,4  Im- 
munotheralr/.  As part of a treatment protocol, recombinant 
human I1.4 was administered intravenously to cancer patients 
three times daily for 3-5 d. PBMC were obtained 1 d before 
I1.4 and immediately after cessation of I1.4 administration. 
After  elutriation  of the  PBMC,  the  monocytes  (>90% 
CD14 4) were cultured and RNA was isolated for Northern 
analysis with the II-1 and I1.1ra cDNA probes.  Although 
low levels of I1.1ra  mRNA were sometimes detectable in 
monocytes from the cancer patients before therapy as repre- 
sented in Fig. 1, a substantial increase in IL-lra gene expres- 
sion was observed in most patients after Ib4 therapy. In con- 
trast, when the same mRNA was probed for I1.1/3, little 
or no Ibl/3 mlLNA was detected before or after Ib4 therapy 
(Fig. 1). Thus, exposure of circulating monocytes to Ib4 in 
vivo results in a selective augmentation of gene expression 
for I1.1ra without a concomitant increase in II-1/3 mRNA. 
To determine if there was a corresponding increase in I1- 
lra protein in these patients, serum samples were collected 
before,  during, and 3-12 wk after I1-4 therapy. These serial 
samples provided internal controls for each patient. Using 
an I1-1ra-specific ELISA, a striking increase in I1-1ra protein 
was measured in the serum of the majority of patients during 
the course of I1-4 therapy (Fig. 2). Whereas pretherapy levels 
for I1-1ra were only 1.3  _+  0.23 ng/ml, the levels increased 
10-fold during therapy (13.54  _+ 3.29; n =  7; p <0.01). The 
increase in serum I1-1ra was transient, since serum collected 
from the same patients 3-12 wk after therapy contained I1- 
lra at or near pretherapy levels (1.9 +_  0.67 ng/ml). In those 
patients whose serum and monocyte mRNA were both avail- 
able for evaluation, a correlation existed between these two 
parameters.  Patients with increased  I1-1ra mRNA also ex- 
pressed high serum I1-1ra levels (patients 1, 2, 3,  and 5 in 
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I1.-4 express increased lblra mRNA. Melanoma and 
renal cell carcinoma patients were given rib4 (10-20 
#g/kg) intravenously for 5 d. Monocytes (2  x  107) 
were isolated from six of these patients before (-) and 
within 24 h after (+) Ib4 treatment, cultured,  and 
total cellular RNA isolated for Northern analysis  with 
the Iblra and IF1 cDNA probes. RNA was moni- 
tored by ethidium  bromide staining  of the 18s and 28s 
ribosomal RNA bands to determine equivalent loading 
of RNA in each lane. 
Fig. 1 had 27.52, 7.03, 5.65, and 20.46 ng/ml serum I1:lra, 
respectively). 
11_,4 Directly Induces IL.Ira Gene Expression and Peptide Secre- 
tion.  Since  monocytes obtained from patients on II,-4 therapy 
expressed substantially  augmented gene expression for I1: 
lra, we examined I1:4 regulation of  monocyte  I1:lra in vitro. 
Elutriated monocytes from normal individuals were incubated 
with varying concentrations of I1:4 for 4 h at 37~  As can 
be seen in Fig. 3 A, II.-4 induced detectable gene expression 
for IL,  lra at concentrations  as low as 0.1 ng/ml (Genzyme 
Corp.) or 10 U/ml (Immunex Corp.), which increased with 
higher concentrations of I1:4. When the I1-4 was preincubated 
with a rabbit polyclonal neutralizing antibody to I1:4 (Gen- 
zyme Corp.), the I1:4-induced increase in monocyte expres- 
sion of I1:lra transcripts was significantly inhibited (data not 
shown). 
To establish whether the I1:4-induced I1:lra gene expres- 
sion was accompanied by IL-lra secretion, monocytes were 
cultured with or without increasing concentrations of I1:4 
for 12-24 h. The supernatants were harvested and I1:lra was 
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Figure 2. 
Pre  During  Post 
IL-4 Therapy 
Serum  levels  of  IL-lra  increase  in patients  during  IL-4 therapy. 
30 
Sera were obtained from patients 1-3 d before administration  of IL-4 (pre), 
during IL-4  treatment (days 3-5), and 3-12 wk after treatment (post).  The 
sera were diluted (1:5) with buffer and assayed  for IL-lra protein by ELISA. 
assayed in the supernatants  by ELISA. IL-4 caused a dose- 
dependent increase in the amount of IL-lra detected in the 
culture supernatants  which plateaued at  12 h (Fig. 3B). 
DifferentiaI  Regulation of  lLlra and II_,I mRNA.  Although 
monocytes exposed to Ib4 in vivo or cultured with II:4 in 
vitro demonstrate increased expression of IL-lra mKNA, no 
Ib13 mRNA could be detected (Fig. 1 and Fig. 4) indicating 
independent and selective regulation of I1:lra.  In the pres- 
ence of LPS, which induces both II-1  and I1:lra (24, Fig. 
4), I1:4 differentially regulates these two members of the I1:1 
family. While augmenting IL-lra mRNA expression, IL,4 dra- 
matically suppresses LPS-induced I1:1/~ mRNA (Fig. 4). The 
net effect of these actions of I1:4 is to neutralize I1:1, both 
by inhibiting IL-1 production and promoting synthesis and 
secretion of its antagonist. 
Kinetics oflLIra Expression.  Based  on the ability of I1:4 
to independently induce only the I1:lra member of the I1:1 
family, we further explored the mechanism of I1:lra regula- 
tion. The kinetics associated with the Ib4-induced expres- 
sion of IL-lra mRNA were determined by culturing elutri- 
ated monocytes  in the absence or presence of I1:4 (1 ng/ml) 
for 30 min up to 24 h. Total cellular RNA was isolated and 
by Northern analysis, monocytes exposed to I1:4 exhibited 
a time-dependent increase in the level of I1:lra gene expres- 
sion with peak levels evident within 2-4 h (Fig. 5). Increased 
expression  was transient as mRNA levels subsided  and returned 
to near baseline by 24 h. Densitometric analysis of the I1:lra 
signals reflected this increase in transcripts which plateaued 
within 2-4 h  and subsequently  declined (Fig. 5). 
Regulation of  lL1ra mRNA  by 11.,4.  To investigate poten- 
tial molecular  mechanisms whereby I1:4 induces increased 
I1:lra transcripts,  the influence of I1:4 on stability of tran- 
scribed mRNA was examined. After a 4-h incubation with 
II:4 (1 ng/ml), actinomycin D  (5/zg/ml), an inhibitor of 
mRNA transcription,  was added to the cultures and at in- 
creasing intervals, the cultures were processed for Northern 
analysis. As shown in Fig. 6 A, the I1:4-induced increase 
in I1:lra mRNA (fivefold) demonstrated a time-dependent 
decrease  after the addition of actinomycin D, reflecting RNA 
degradation. Although control (non-Ib4 treated) monocytes 
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tion of IL-1 and 1131ra by Ib4. 
Monocytes were cultured in sus- 
pension with Ib4 (1,000 U/ml) 
only, LPS (1/~g/ml), or LPS with 
II:4. RNA was harvested  from the 
calls after 4 h and processed for 
Northern analysis  with the Iblra 
and IL-1B  cDNA probes. Equiva- 
lent  loading  of  the  lanes  was 
monitored  by the constitutive ex- 
pression of the He7 housekeeping 
gene. 
Figure 3.  IL-4  induces monocyte expression of IL-lra mRNA and pro- 
tein. (A) Monocytes (2  x  107) were cultured with II34 (0.01-10 ng/ml 
[Genzyme Corp.] or 10-10,000 U/ml [Immunex  Corp.]) for 4 h and RNA 
was extracted and processed for Northern analysis with the Iblra and IL- 
1~ cDNA probes. Equivalent loading of lanes was monitored by constitu- 
tive expression  of the He7 housekeeping  gene. (B) Supernatants from mono- 
cytes (106/ml) cultured with Ib4 (0-10 ng/ml [Genzyme Corp.]) in 24- 
well culture plates at 37~  for 12 h were harvested, filtered, and assayed 
for I131ra peptide by ELISA. 
formation, prevents protein synthesis. Although the addition 
of Cx (0.5 or 1.0 #g/ml) did not augment Iblra mRNA 
in the absence of II-4, the inclusion of  Cx with Ib4 increased 
expression of  I1,1ra mRNA two- to threefold above the levels 
observed for II-4 alone (Fig 6 B). According to these data, 
a short-lived or labile protein may be involved in the regula- 
tion of I1-1ra expression. 
To document a transcriptional regulation of I1-1ra by I1-4, 
nuclear runoff experiments were performed in which nuclei 
from monocytes cultured with either medium alone or I1-4 
were allowed to synthesize mRNA for a defined period of 
time in vitro. The resulting transcripts were then hybridized 
to cDNA probes (pGEM vector control, I1-1ra, and GAPDH) 
generally do not constitutively express detectable steady-state 
levels of I1,1ra mlLNA, occasional donor cells were positive 
for I1,1ra transcripts. To compare the message stability in the 
absence and presence of I1,4, the data represented in Fig. 6 
are from a donor with low, but detectable levels of  uninduced 
I1,1ra mlLNA. No differences were observed in the half-life 
of the mRNA irrespective of the addition of I1,4. When the 
mRNA  bands  were  analyzed  densitometrically  and  the 
resulting values plotted vs time, the approximate half-life of 
Iblra calculated from the decay curves was 2.5-3 h (Fig. 6 
A). These data suggest that I1.-4 does not increase  the amount 
of Iblra mRNA only through a stabilization of the mRNA 
molecule. 
Iblra gene expression was further examined in the pres- 
ence of  cycloheximide  (Cx) which, by inhibiting peptide bond 
Figure 5.  Kinetics of Ib4 induction  of IL-lra. Monocytes were incubated 
in suspension with Ib4 (1 ng/ml [Genzyme Corp.])  for 0-24 h during 
which RNA was isolated and probed for IL-lra transcripts by Northern 
analysis, where He7 cDNA served as a housekeeping control.  Resulting 
bands were analyzed by densitometry and results are expressed as arbitrary 
densitometric  units. 
778  IL-4 Induces IIA Receptor  Antagonist Figure 6.  Regulation  of IL-lra mRNA by Ib4. (A) Monocytes  were 
cultured in the presence  or absence  of IL-4 (10 ng/ml [Genzyme  Corp.]) 
for 4 h after  which  actinomycin  D (5/~g/ml)  was added.  At the indicated 
times, RNA was isolated  for Northern blot analysis.  The resulting RNA 
bands were analyzed  densitometricaUy  and the resulting values plotted 
against time. (B) Monocytes  were  cultured  with or without Ib4 (10 ng/ml) 
in the presence  or absence  of Cx (0.5-1.0/~g/ml) for 4 h at 37~  and 
RNA harvested for Northern analysis. (C) After monocytes  (5  x  107) 
were  cultured  in the presence  or absence  of  IL-4 (10 ng/ml) for 4 h, nuclei 
were  isolated and a nuclear  runoff  assay  performed,  pGEM  cDNA served 
as a vector control, whereas  GAPDH cDNA served  as a housekeeping 
control. 
fixed on  nitrocellulose filters.  A  threefold increase in  the 
amount of synthesized transcripts for ILlra occurred after 
monocytes had been cultured with IL-4 (Fig.  6 C), consis- 
tent with a direct effect of IL-4 on the rate of transcription. 
Discussion 
Originally defined by its ability to promote B cell growth 
and IgE synthesis, continuing exploration of the role of IL-4 
in host defense has revealed its significant ability to suppress 
numerous mononuclear phagocyte functions (6-10) and pro- 
mote programmed cell death (25).  In this study, we define 
yet another mechanism whereby Ib4 may suppress  the im- 
mune response as  shown in cancer patients  receiving IL-4 
therapy. In these patients, we demonstrate that systemically 
administered IL-4 sdectively induces transcription and trans- 
lation of IL-lra, a competitive inhibitor of the multifunctional 
cytokine, IL-1. Induced circulating levels of IL-lra may pro- 
vide an immunosuppressive signal not inconsistent with the 
lack of augmented tumoricidal activity observed in these pa- 
tients (26).  Although LPS (24),  TGF-B (27, 28), and GM- 
CSF (24, 29) also induce IL-lra, each of these mediators also 
induces variable amounts of IL-1. As shown here and in re- 
cent studies (14, 30), 1D4 appears unique in its ability to selec- 
tively induce IL-lra in resting monocytes without affecting 
IL-1, whereas in monocytes stimulated by LPS (15,  16, 30, 
and Fig. 4) or TGF-fl (Wahl, S., G. Costa, H.  Wong, and 
M. Brandes, manuscript submitted for publication), IL-4 not 
only augments IL-lra, but it dramatically inhibits IL1B ex- 
pression. In the tumor patients receiving exogenous IL-4, a 
number  of compromised  monocyte functions  have  been 
ascribed to IL-4 coincident with the increased expression of 
IL-lra  (7), which document its immunosuppressive poten- 
tial. Moreover, elevated endogenous levels of II.-4, as occur 
in visceral leishmaniasis (31), are also reflected by suppressed 
monocyte functions and defects in cell-mediated immunity. 
There are several possible mechanisms whereby IL-4 may 
influence Iblra gene transcription and monocyte function. 
The Ib4-induced accumulation of IL-lra message appeared 
not to be due only to a decreased rate of degradation, and 
by performing nuclear runoff experiments, Ib4 was shown 
to induce an increase in the rate of transcription.  Further- 
more, the ability of Cx to superinduce IL-4-mediated IL-lra 
mRNA suggests that a regulatory protein may exist to re- 
press  transcription, possibly by interacting with a negative 
regulatory element in the promoter region of the Iblra gene 
(32).  Although the region that is located 294 bp proximal 
of the promoter contains the critical sequences necessary for 
regulated expression of IL-lra transcripts, it is unlikely that 
a putative labile protein repressor acts directly at the tran- 
scriptional level since Cx does not affect the production of 
IL-lra mRNA in the absence of Ib4.  It is conceivable that 
Ib4 interacts directly with a labile cytosolic regulatory mol- 
ecule, and a depletion of this molecule may modulate IL-4 
effects on the cell.  Dissecting these pathways is crucial to 
defining the reciprocal effects of IL-4 on IL-13  and IIr 
By competitively blocking Ibl binding to the IL-1R and 
lacking  any  agonist  effect,  IL-lra  exerts  a  variety  of an- 
tiinflammatory activities.  For example, IL-l-mediated leuko- 
cyte adhesion to vascular endothdium is blocked by IL-lra 
(33).  The antagonist also reverses IL-l-induced production 
of PGE2  and collagenase by fibroblasts,  synoviocytes, and 
chondrocytes in culture (34, 35). Moreover, as an inhibitor 
of Ibl-induced degradation of proteoglycans and of glycos- 
aminoglycan synthesis in cartilage explants (36),  Iblra has 
been proffered as a potential therapeutic agent for arthritic 
lesions.  Taking these in vitro observations a step further, IL- 
lra has been administered in vivo and found to block Ibl-in- 
duced accumulation of leukocytes in inflamed  joints (37, 38), 
and to reduce proteoglycan release  from articular cartilage 
779  Wong  et al. (37). The demonstrated ability of IL,  lra to ameliorate  arthritis 
in both  the  type II collagen model (39)  and the bacterial 
cell wall model (40) has prompted clinical  trials of this an- 
tagonist  in rheumatoid  arthritis  (41). 
Although IL-lra is an important antiinflammatory agent, 
IL-4, which not only induces IL-lra production, but also has 
numerous additional antiinflammatory effects,  may prove a 
more effective inhibitor of chronic or aberrant immune func- 
tion.  In this regard,  recent studies in bacterial cell wall-in- 
duced arthritis  have documented that  systemic administra- 
tion of I1.-4 does, in fact, increase expression of Iblra in the 
arthritic  animals  with  a  concomitant  decrease  in  mono- 
cyte-macrophage functions, and suppression of  joint swelling 
and tissue destruction  (42; Allen, J.,  H. Wong,  G.  Costa, 
M. Bienkowski, and S. Wahl, manuscript submitted for pub- 
lication). These observations are consistent with the induc- 
tion  of IL-lra  in  cancer patients  receiving  exogenous II~4 
therapy in this study, and suggest that  the use of systemi- 
cally administered II:4 may have important clinical significance 
as an antiinflammatory  agent,  especially in chronic inflam- 
matory disease.  Parenthetically,  although  no demonstrable 
antitumor effects were observed in the cancer patients treated 
with  IL4 alone  (26),  one patient  with  a chronic psoriatic 
condition improved clinically during the course of IL-4 treat- 
ment (Lotze, M., unpublished observation). Through the in- 
duction of IL-lra and its emerging spectrum of monocyte in- 
hibitory activities, IL-4 may prove to have important clinical 
applications. 
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